Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate risk of cancer incidence and mortality associated
with the use of REGRANEX (becaplermin) in patients with diabetes who are members of a U.S.
Veterans Health Administration.
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.